


## DB0614

<b>Cat. No.:</b>	HY-148063		
<b>CAS No.:</b>	2769753-47-9		
<b>Molecular Formula:</b>	C <sub>41</sub> H <sub>42</sub> N <sub>8</sub> O <sub>7</sub> S <sub>2</sub>		
<b>Molecular Weight:</b>	822.95		
<b>Target:</b>	AAK1; Aurora Kinase; CaMK; CDK; Ferroptosis; PROTACs; Salt-inducible Kinase (SIK); ULK; Wee1; LIM Kinase (LIMK)		
<b>Pathway:</b>	Neuronal Signaling; Cell Cycle/DNA Damage; Epigenetics; Apoptosis; PROTAC; Immunology/Inflammation; Autophagy		
<b>Storage:</b>	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



### SOLVENT & SOLUBILITY

#### In Vitro

DMSO : 2.78 mg/mL (3.38 mM; ultrasonic and warming and adjust pH to 5 with HCl and heat to 60°C)

Preparing Stock Solutions	Solvent Concentration	Mass		
		1 mg	5 mg	10 mg
	1 mM	1.2151 mL	6.0757 mL	12.1514 mL
	5 mM	---	---	---
	10 mM	---	---	---

Please refer to the solubility information to select the appropriate solvent.

### BIOLOGICAL ACTIVITY

#### Description

DB0614 (Example 21) is a bifunctional compound targeted protein degradation of kinases. DB0614 degrades AAK1, AURKA, BMP2K, CAMKK1, CDK16, CML, CDK6, EIF2AK2, FER, GAK, LCK, LIMK2, MAP3KH, MAPK8, MAPK9, NEK9, PLK4, PTK2B, SIK2, STK17A, STK17B, ULK1, ULK3, and WEE1. DB0614 can be used for research of disease or disorder mediated by aberrant kinase activity<sup>[1]</sup>.

#### IC<sub>50</sub> & Target

CDK6	CDK16/Cyclin Y	ULK1	Aurora Kinase
SIK2	LIMK2		

### REFERENCES

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA